Logotype for Xencor Inc

Xencor (XNCR) investor relations material

Xencor Study Result summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Xencor Inc
Study Result summary24 Oct, 2025

Study design and patient population

  • Phase 1, multicenter, open-label, dose-escalation and expansion study of XmAb819 in advanced clear cell RCC, with both IV and SC cohorts; data cut-off September 19, 2025.

  • 69 heavily pretreated patients enrolled, all with prior anti-PD1 and VEGF-TKI therapy; median of 4 prior regimens, 36% had HIF2α inhibitor exposure.

  • No preselection for ENPP3 expression, but retrospective testing confirmed most were high expressors.

  • Study objectives include safety, tolerability, pharmacokinetics, and anti-tumor activity using a 3+3+3 dose-escalation design.

Safety and tolerability

  • XmAb819 was generally well tolerated, with 4% discontinuation due to adverse events and over 90% reaching target dose.

  • Most common adverse events were CRS, rash, and GI toxicities, mainly Grade 1 or 2; Grade 3 CRS was 4% with correct dosing.

  • No treatment-related ICANS or Grade 5 events; most adverse events were manageable and transient.

  • Dose prep errors led to higher Grade 3 CRS rates (28% in error group vs 4% with correct prep); mitigated by site retraining and new formulation planned for 2026.

  • Grade 3 treatment-related events included rash (16%) and liver enzyme elevations (7%); one dose-limiting Grade 4 liver enzyme elevation.

Efficacy and clinical activity

  • In the target dose range, XmAb819 showed a 25% objective response rate (all partial responses) and 70% disease control rate in heavily pretreated patients.

  • Majority of patients experienced tumor reduction, with sustained disease control and some deepening responses over time.

  • Responses included patients with prior progression on belzutifan and those with low ENPP3 expression.

  • 50% of efficacy-evaluable patients in the target dose range remain on treatment; all five responders remain on therapy.

  • One patient with initial progression had a 47% reduction in lesions and remains on treatment.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Xencor earnings date

Logotype for Xencor Inc
Q3 20254 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Xencor earnings date

Logotype for Xencor Inc
Q3 20254 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Xencor Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and cytokine therapies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology to create antibody-based therapies that enhance immune responses or modulate immune activity. Xencor's pipeline includes candidates designed to target specific proteins involved in disease processes, aiming to provide more effective and durable treatments. The company is involved in both internal research and collaborations with other biopharma companies to advance its therapies through clinical trials. The company is headquartered in Monrovia, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage